Introduction
============

Liver receptor homologue 1 (LRH-1), also known as nuclear receptor subfamily 5 group A member 2 (NR5A2), is a member of the NR5A subfamily of NRs that was originally found in the liver of mice, and then later in rats, chickens, horses, zebrafish, frogs and the human body ([@b1-ol-0-0-8988]). Since then, it has been shown to be involved in the development of a variety of malignant tumors, including breast, liver, gastric, colon and pancreatic cancer ([@b2-ol-0-0-8988]--[@b4-ol-0-0-8988]). LRH-1 is involved in regulating numerous functions, with studies showing that it participates in the metabolism, differentiation and development of organisms ([@b4-ol-0-0-8988]--[@b6-ol-0-0-8988]). LRH-1 also regulates a variety of biological processes, including bile acid metabolism ([@b7-ol-0-0-8988]), reverse cholesterol transport ([@b8-ol-0-0-8988]) and glucose balance in the human body ([@b9-ol-0-0-8988]). Recently, LRH-1 was found to serve a decisive role in controlling the development of neural stem cells ([@b10-ol-0-0-8988]). Therefore, LRH-1 has been identified as a specific tumor marker for the evaluation of disease in patients with cancer.

The association between the expression and prognosis of LRH-1 in malignant tumors has been investigated by certain studies. Although, it has been shown that LRH-1 is highly expressed in colon cancer ([@b11-ol-0-0-8988]), there is no research showing the association between its positive expression and prognosis. The following study was undertaken in order to investigate the expression of LRH-1 in colon cancer and its association with the prognosis of affected patients.

Materials and methods
=====================

### Patients and tissue samples

A total of 128 colon cancer tissue samples of different stages obtained between April 2011 and December 2011 were randomly collected from the Department of Gastrointestinal Surgery in The First People\'s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University (Changzhou, Jiangsu, China). The selected tissue samples were routinely preserved in 10% buffered neutral formalin at 24°C for 12 h. The normal tissues were removed from at least 5 cm away from the edge of these tumors. All cases of colon cancer were clinically and pathologically proven, and all of the patients recruited in this study had not received neoadjuvant chemotherapy or preoperative radiotherapy. All patients provided written informed consent prior to the collection and the research program used in the study was approved by the Ethical Committee of The Third Affiliated Hospital of Soochow University. Tumor, Node, Metastasis (TNM) stages and clinicopathological classification were defined based on the Union for International Cancer Control classification ([@b12-ol-0-0-8988]). Patients received telephone follow-up or outpatient review until December 2016 or mortality.

### Immunohistochemical analysis

Immunohistochemical staining was performed using the Elivsion two-step method ([@b13-ol-0-0-8988]). The following primary antibody was used: LRH-1 (1:100 dilution; catalog no. NBP1-90094; Novus Biologicals, LLC, Littleton, CO, USA). The secondary antibody (1:100 dilution; catalog no. kit-0028) and DAB solution were provided by Maxim Biomedical, Inc. (Fuzhou, China). All samples were fixed in 10% formalin at 24°C for 12 h solution and embedded in paraffin. Sections (3--4 mm) were dewaxed in xylene, dehydrated in ethanol (75, 95 and 100%), and incubated in 3% H~2~O~2~ for 15 min to destroy the activity of endogenous peroxidase. Following incubation in 10% bovine serum (dissolved in PBS at 24°C; Novus Biologicals, LLC, Littleton, CO, USA) for 10 min, each slide was incubated with the primary antibody at 4°C overnight. The aforementioned biotin-labeled mouse-rabbit immunoglobulin was selected as the secondary antibody. Staining using the DAB Detection kit (Polymer) (cat. no. kit-0014; Maxim Biomedical, Inc.) was performed according to the manufacturer\'s protocol, and sections positive for colon cancer were selected as positive controls, with non-immune animal serum IgG replacing the antibody as a negative control.

All tissue specimens were evaluated separately by two pathologists who were unaware of the clinicopathological status of the patients. Five high magnification fields of view were selected randomly from each section. The main expression of LRH-1 was found in the cytoplasm and shown as a tan or brown color. The scoring of the positive cell count fraction was determined as follows: Score 0, ≤5; score 1, 6--25; score 2, 26--50; score 3, 51--75; and score 4, \>75%. The scoring of the staining intensity and the dyeing depth was determined as follows: Score 0, no staining (colorless); score 1, weak staining (yellow); score 2, moderate staining (pale brown); and score 3, strong staining (sepia). The total score was calculated by multiplying the staining intensity fraction with the positive cell count fraction. A total score of \<5 was considered as negative expression of LRH-1, and a score of ≥5 was considered as positive expression of LRH-1.

### Statistical analysis

All statistical analyses were accomplished with the SPSS 17.0 statistical software (SPSS, Inc. Chicago, IL, USA). The association between LRH-1 expression and the clinicopathological characteristics was tested using the non-parametric χ^2^ test. The overall survival (OS) curves were plotted using the Kaplan-Meier method, and the positive and negative expression of LRH-1 samples was compared using the log-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of LRH-1 in colon cancer tissues and adjacent normal tissues

The clinicopathological characteristics of the 128 patients who were recruited in the present study are shown in [Table I](#tI-ol-0-0-8988){ref-type="table"}. Among the patients, 42 were female and 86 were male, with a mean age of 58.38±8.3 years (range, 38--82 years). A total of 63 cases were tubular adenocarcinoma, 25 were mucinous adenocarcinoma, 28 were papillary adenocarcinoma and 12 were squamous cell carcinoma; 65 cases were located in the rectum and sigmoid colon, 37 in the right colon and 26 in the left colon. In terms of differentiation degree, 55 cases highly differentiated, 33 were moderately differentiated and 40 were poorly differentiated. The number of cases at stages I, II, III and IV was 40, 21, 60 and 7, respectively. The expression of LRH-1 in the 128 pairs of resected specimens (including tumor tissue samples and matched adjacent normal tissue samples) from patients who were diagnosed with colon cancer was determined by immunohistochemistry. It was found that 108/128 colon cancer tissues exhibited significantly LRH-1 expression higher compared with 17/128 adjacent non-cancerous tissue ([Table II](#tII-ol-0-0-8988){ref-type="table"}). The expression of LRH-1 in the colon cancer tissues was significantly higher than that in the adjacent tissues ([Fig. 1](#f1-ol-0-0-8988){ref-type="fig"}).

### Association of LRH-1 with different clinicopathological characteristics

The association between the expression level of LRH1 and the common clinicopathological parameters of colon cancer, including sex, age, TNM stage, pathological type, tumor location, degree of differentiation, depth of tumor invasion (pT), lymph node metastasis (pN) and distant metastasis, were analyzed ([Table III](#tIII-ol-0-0-8988){ref-type="table"}). The level of LRH-1 expression was not found to be associated with the sex, age, tumor location, distant metastasis, degree of differentiation or pathological type of the colon cancer patients, but was significantly associated with the clinicopathological stage, depth of tumor invasion and lymph node metastasis.

### Association between LRH-1 expression levels and the prognosis of patients

The 5-year OS rate of patients with negative and positive LRH-1 expression was investigated by Kaplan-Meier survival curves and the log-rank test, as shown in [Fig. 2](#f2-ol-0-0-8988){ref-type="fig"}. A total score of \<5 was considered as negative expression of LRH-1, and a score of ≥5 was considered as positive expression of LRH-1Among the 128 patients who were followed up for 5 years, 2 were lost to follow-up. Of the 128 patients, 82 survived this period, and the 5-year OS rate was 64.1%. Moreover, the 5-year OS rates for patients with negative and positive LRH-1 expression were 85.0 and 60.2%. The median estimated cumulative survival time was significantly lower in the LRH-1 positive expression group \[46 months; 95% confidence interval (CI), 42.729--49.938 months\] compared with that in the LRH-1 negative expression group (54 months; 95% CI, 48.106--60.494 months). These results suggest that patients with high levels of LRH-1 expression have a worse prognosis compared with patients with low levels of LRH-1 expression.

Discussion
==========

The development of tumors and a variety of malignant behaviors are the outcome of the combined action of multiple genes, and in general, it is a complex multi-step and multi-factor process ([@b14-ol-0-0-8988]). The overexpression and activation of proto-oncogenes, the inhibition or downregulation of tumor suppressor genes and the downregulation of mutations serve an important role in the development of tumorigenesis. Excessive proliferation and blocked apoptosis are basic characteristics of tumor cells, which are associated with the regulation of proliferation, apoptosis and the cell cycle of important signal pathway disorders, and even loss of function ([@b15-ol-0-0-8988],[@b16-ol-0-0-8988]). Therefore, it is important to investigate the abnormal expression of genes associated with malignancy for determining tumor diagnosis, treatment and prognosis. In view of the abnormal expression of LRH-1 in a variety of malignant tumors ([@b11-ol-0-0-8988]), including gastric, breast and pancreatic cancer, the present study investigated the expression of LRH-1 in colon cancer and its association with the prognosis of patients.

LRH-1 is a member of the NR5A subfamily of NRs; it is expressed in numerous organs, including the liver, pancreas, colon and ovaries ([@b6-ol-0-0-8988]). LRH-1 serves an important role in the body, controlling the development and differentiation of animal embryos, the production of the steroid hormone and the metabolism of bile acid ([@b17-ol-0-0-8988]). LRH-1 exhibits increased expression in pancreatic cancer cells and can promote its proliferation by activating cyclin D1, cyclin E1 and c-Myc ([@b18-ol-0-0-8988],[@b19-ol-0-0-8988]). Furthermore, LRH-1 is highly expressed in breast cancer, promoting tumor cell growth via an increased synthesis of local estrogen ([@b20-ol-0-0-8988]). LRH-1 is involved in the renewal of intestinal cells in the gastrointestinal tract, and is expressed in gastric cancer and colon cancer cells. Zhang *et al* ([@b21-ol-0-0-8988]) found that LRH-1 gene polymorphisms (rs3790843 and rs3790844) increased the risk of local lymph node and distant metastasis. Kramer *et al* ([@b22-ol-0-0-8988]) confirmed the high expression of LRH-1 in colorectal cancer tissues and cells, and indicated that LRH-1 can promote the growth of colorectal cancer cells by inhibiting the expression of the cyclin-dependent kinase inhibitor 1A gene in the HCT116 and HT29 cell lines. Bayrer *et al* ([@b23-ol-0-0-8988]) showed that the inhibition of LRH-1 expression can weaken the ability of metastases of colon cancer cells, and can change the expression of associated genes. The present study found that colon cancer tissue exhibited positive LRH-1 expression, and the expression rate was 64.7%, higher than that of the adjacent tissue at 32.2%, which is consistent with the aforementioned results in pancreatic cancer and breast cancer. This indicates that the expression level of LRH-1 in colon cancer and other malignant tumors is abnormally elevated. Further analysis revealed that LRH-1 expression was associated with clinicopathological stage, depth of tumor invasion and lymph node metastasis; for example, the positive expression rate of LRH-1 in stage III and IV was 95.5%, which was higher than that in stage I and II, suggesting that if the Tumor-Node-Metastasis (TNM) stage of colon cancer was higher then the positive expression rate would be higher. This study also found that the expression rate of LRH-1 in colon cancer tissues with T3+T4 depth was also higher than that in patients with lymph node metastasis and distant metastasis, and the expression of LRH-1 in patients with lymph node metastasis and distant metastasis was significantly higher than that in patients without lymph node metastasis. However, there is no cytological evidence that LRH-1 expression is directly involved in the malignant transformation of colon cancer and its transformation mechanism. Our next study intends to verify the effect of LRH-1 on colon cancer cells. In the present study, the 5-year survival rate was determined and it was found that LRH-1 positive expression was associated with poor prognosis. The median OS time of patients with positive expression was 46 months, which was lower than that of patients with negative expression at 54 months. The poor prognosis may be related to positive expression of LRH-1, associated with TNM stage, depth of invasion and lymph node metastasis.

In summary, LRH-1 is mainly expressed in colon cancer tissues, and is associated with the depth of tumor invasion, lymph node metastasis and clinicopathological stage. The prognosis of patients with positive LRH-1 expression is significantly worse than that of patients with negative expression. These results suggest that LRH-1 may serve an important role in the development and progression of colon cancer. The detection of LRH-1 expression can be used to assist in the diagnosis and evaluation of colon cancer.
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![LRH-1 is highly expressed in colon cancer tissues. (A) Colon cancer tissues with a positive LRH-1 immunohistochemical reaction. (B) Adjacent normal tissues negative for LRH-1. Magnification, ×200. LRH-1, liver receptor homologue 1.](ol-16-03-2833-g00){#f1-ol-0-0-8988}
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###### 

Demographic and pathological parameters of colon cancer patients.

  Parameter                    Value, n (%)
  ---------------------------- --------------
  Sex                          
    Male                       86 (67.2)
    Female                     42 (32.8)
  Age, years                   
    ≥60                        83 (64.8)
    \<60                       45 (35.2)
  Pathological type            
    Tubular adenocarcinoma     63 (49.2)
    Mucinous adenocarcinoma    25 (19.5)
    Papillary adenocarcinoma   28 (21.9)
    Squamous cell carcinoma    12 (9.4)
  Tumor location               
    Rectum and sigmoid colon   65 (50.8)
    Right colon                37 (28.9)
    Left colon                 26 (20.3)
  Distant metastasis           
    Absent                     121 (94.5)
    Present                    7 (5.5)
  pT stage                     
    T1                         35 (27.3)
    T2                         20 (15.6)
    T3                         66 (51.6)
    T4                         7 (5.5)
  pN stage                     
    N0                         61 (47.7)
    N1+N2                      67 (52.3)
  TNM stage                    
    I                          40 (31.2)
    II                         21 (16.4)
    III                        60 (46.9)
    IV                         7 (5.5)
  Differentiation              
    High                       55 (43.0)
    Moderate                   33 (25.8)
    Poor                       40 (31.2)

TNM, tumor-node-metastasis.

###### 

Expression of LRH-1 in colon cancer tissue and adjacent non-cancerous tissue (ANCTs).

                            LRH-1 expression                   
  ------------------------- ------------------ ----- --------- ---------
  Colon cancer tissues, n   20                 108   129.462   \<0.001
  ANCTs, n                  111                17              

LRH-1, liver receptor homologue 1; ANCT, adjacent non-cancerous tissue.

###### 

Association between LRH-1 expression and clinicopathological features of colon cancer patients.

                               LRH-1 expression, n                                                               
  ---------------------------- --------------------- ----- ----------------------------------------------------- ------------------------------------------------------
  Sex                                                                                                            
    Male                       12                    74    0.555                                                 0.605
    Female                     8                     34                                                          
  Age, years                                                                                                     
    ≥60                        16                    67    2.389                                                 0.136
    \<60                       4                     41                                                          
  Pathological type                                                                                              
    Tubular adenocarcinoma     9                     54    0.204                                                 0.982
    Mucinous adenocarcinoma    4                     21                                                          
    Papillary adenocarcinoma   5                     23                                                          
    Squamous cell carcinoma    2                     10                                                          
  Tumor location                                                                                                 
    Rectum and sigmoid colon   14                    51    4.585                                                 0.102
    Right colon                5                     32                                                          
    Left colon                 1                     25                                                          
  Distant metastasis                                                                                             
    Absent                     20                    101   1.371                                                 0.371
    Present                    0                     7                                                           
  pT                                                                                                             
    T1                         8                     27    4.878^[a](#tfn3-ol-0-0-8988){ref-type="table-fn"}^    0.030^[a](#tfn3-ol-0-0-8988){ref-type="table-fn"}^
    T2                         4                     16                                                          
    T3                         8                     58                                                          
    T4                         0                     7                                                           
  pN                                                                                                             
    N0                         17                    44    13.252                                                \<0.001
    N1+N2                      3                     64                                                          
  TNM stage                                                                                                      
    I                          12                    28    13.252^[b](#tfn4-ol-0-0-8988){ref-type="table-fn"}^   \<0.001^[b](#tfn4-ol-0-0-8988){ref-type="table-fn"}^
    II                         5                     16                                                          
    III                        3                     57                                                          
    IV                         0                     7                                                           
  Differentiation                                                                                                
    High                       10                    45    5.677                                                 0.055
    Moderate                   1                     32                                                          
    Poor                       9                     31                                                          

T1-T2 vs. T3-T4

I--II vs. III--IV. LRH-1, liver receptor homologue 1; TNM, tumor-node-metastasis.

[^1]: Contributed equally
